SIStockInvestingSI.com

NASDAQ · INSM · Biotechnology

Insmed Incorporated (INSM) stock analysis

$94.04−1.70%Data as of Oct 21, 2026
  • INSM lost 22.2% over the past month versus 0.0% for the S&P 500, ranking 97th of 100 Nasdaq 100 stocks.
  • Over 12 months it returned −44.0%, 59.8 points behind the S&P 500, and trades 55.5% below its 52-week high.
  • In the last 30 days 2 analysts raised earnings estimates and 2 cut; forward EPS moved −1.4% (+255.0% over 90 days).
  • It sits in the Biotech segment of the Healthcare Value Chain, where the 1-month median return is +0.4%.
  • The daily chart reads Intermediate downtrend · Decline (since Oct 16, 2026).
Market cap$20.5B
12-month return−44.0%
Forward P/E122.7×
Mean target vs price+108.6%

One-year price with 50- and 200-day averages

Open in Hub
101135168202JanAprJulOct
94.0450-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

INSM−22.2%
Sector median−8.7%
S&P 5000.0%
INSM−12.4%
Sector median−5.4%
S&P 500+4.7%
INSM−34.9%
Sector median−1.5%
S&P 500+8.7%
INSM−44.0%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the Nasdaq 10097 / 100
3-month rank in its sector · Healthcare426 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Intermediate downtrend · DeclineConfirmed

Holding since Oct 16, 2026

  • Close below EMA20 below EMA50
  • EMA50 fell over the last ten sessions
This pattern on this stock

76 occurrences in 10 years. The median move over the next 20 sessions was −3.5%, positive 46% of the time, against +0.9% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$0.73
30-day change−1.4%
90-day change+255.0%
Mean target$196.14 +108.6%
Raised (30d) 2Cut (30d) 2

22 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersGrowth

Behind peersValuation, Momentum

PeersVRTX · MRNA · REGN · ARGX

Where it sits in the supply chain

Healthcare Value Chain · Drugs & devices

Explore the full chain map in Hub
Supplied by
Life-science tools & bioprocessing+6.0%
TMO+5.4%1 monthDHR+6.0%1 monthA+6.4%1 month
Clinical research outsourcing+8.0%
IQV+2.4%1 monthFTRE+17.8%1 monthICLR+10.9%1 monthMEDP+5.1%1 month
Its segment
Biotech+0.4%
AMGN+6.8%1 monthREGN+0.2%1 monthGILD+0.6%1 monthVRTX+1.9%1 monthALNY−10.6%1 monthMRNA+34.6%1 monthBIIB+6.9%1 monthINSM−22.2%1 monthINCY−10.6%1 monthCATX−22.3%1 month

Built on a few major drugs or platforms, with shares highly sensitive to trial data and regulatory decisions.

Sells into
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−56.5%
Volatility, 60D79.1%
From 52-week high−55.5%
From 52-week low+2.4%
Forward P/E122.7×

Themes

  • Biotech Platform3M rank 189 / 414
AMGNAmgenREGNRegeneron PharmaceuticalsGILDGilead SciencesVRTXVertex PharmaceuticalsALNYAlnylam Pharmaceuticals, Inc.MRNAModerna, Inc.BIIBBiogen Inc.INCYIncyte Corporation

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗